You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

356 Results
Regimen
Intent: Palliative, Adjuvant
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
Apr 2023
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
Exceptional Access Program
    everolimus - Treatment of metastatic renal cell carcinoma (mRCC) as second or third line therapy in patients
    previously treated for mRCC with a funded tyrosine kinase inhibitor (TKI), with specific criteria
Mar 2023
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Funding:
New Drug Funding Program
    Panitumumab - Metastatic Colorectal Small Bowel or Appendiceal Cancer
Aug 2023
Regimen
Intent: Curative
Funding:
New Drug Funding Program
    Cetuximab and Radiation - Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Jul 2023
Regimen
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) - Single Agent - Indolent Lymphoma
Nov 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma
Nov 2023
Regimen
Cancer Type:
Sarcoma, 
Osteogenic / Bone
Intent: Adjuvant, Neoadjuvant, Palliative
Nov 2023
Regimen
Regimen

Pages